HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- ethyl- 3- O- sulfamoylestra- 1,3,5(10)16- tetraene

structure in first source

Also Known As:

2-ethyl-3-O-sulphamoyl-estra-1,3,5(10) 16-tetraene; ESE-16

Networked: 7 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Estranes
      - Estrenes
        2-ethyl-3-O-sulfamoylestra-1,3,5(10)16-tetraene: 7
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - 2-ethyl-3-O-sulfamoylestra-1,3,5(10)16-tetraene: 7
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - 2-ethyl-3-O-sulfamoylestra-1,3,5(10)16-tetraene: 7

Experts

1.	McKenna, Robert: 3 articles (03/2014 - 01/2013)
2.	Joubert, Annie Margaretha: 2 articles (01/2015 - 01/2013)
3.	Joubert, Annie: 2 articles (03/2014 - 01/2014)
4.	Sippel, Katherine: 2 articles (03/2014 - 01/2014)
5.	Wolmarans, Elize: 2 articles (03/2014 - 01/2014)
6.	Coetzee, Magdalena: 1 article (01/2021)
7.	Helena, Jolene: 1 article (01/2021)
8.	Joubert, Anna: 1 article (01/2021)
9.	Lakier, Roy: 1 article (01/2021)
10.	Mabeta, Peace: 1 article (01/2021)

Related Diseases

1.	Carcinoma (Carcinomatosis) 03/01/2014 - "In this study, it was demonstrated that ESE-16 induces cell death via both autophagy and apoptosis in esophageal carcinoma cells. " 01/01/2014 - "This was the first in vitro study conducted to investigate the action mechanism of ESE-16 on an esophageal carcinoma cell line. " 01/01/2014 - "In this study, it was investigated whether ESE-16 is capable of inducing apoptosis in vitro in the esophageal carcinoma SNO cell line via the intrinsic pathway at a concentration of 0.2 μM with an exposure time of 24 hours. " 03/01/2014 - "The new in silico-designed estradiol analogue 2-ethyl-3-O-sulfamoylestra-1,3,5(10)16-tetraene (ESE-16) was investigated in terms of its in vitro antiproliferative effects on the esophageal carcinoma SNO cell line at a concentration of 0.18 μM and an exposure time of 24 h. "
2.	Neoplasms (Cancer) 01/01/2015 - "This is the first ex vivo study reporting on involvement of apoptosis- and autophagy-related targets in platelets after exposure to ESE-16, warranting further investigation in platelets of cancer patients." 02/10/2023 - "These results justify further investigation of ESE-16 as a radiation-sensitizing agent since pre-exposure appears to augment the response of tumor cells to radiation."
3.	Adenocarcinoma 08/27/2013 - "This study investigated ESE-16 for its anti-proliferative potential on a cervical adenocarcinoma cell (HeLa) cell line. "
4.	Breast Neoplasms (Breast Cancer) 02/10/2023 - "Here, we investigated whether pre-exposure of breast cancer cells to low-dose ESE-16 would affect radiation-induced deoxyribonucleic acid (DNA) damage and the consequent repair pathways. " 01/01/2013 - "Signaling pathways of ESE-16, an antimitotic and anticarbonic anhydrase estradiol analog, in breast cancer cells."
5.	Neoplasm Metastasis (Metastasis) 01/01/2021 - "In this proof-of-concept study, the potential radiosensitizing effects of ESE-16 were investigated in an in vitro deconstructed bone metastasis model. "

Related Drugs and Biologics

1.	Estradiol (Delestrogen)
2.	Antimitotic Agents
3.	Radiation-Sensitizing Agents
4.	DNA (Deoxyribonucleic Acid)